Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 to 60

Dexmedetomidine vs remifentanil as anesthesia aids for ECT

Official title: Comparison of Three Different Anesthetic Methods in ECT

Run by Inonu University · NCT07824817 · Data updated 2026-11-12

This study tests whether dexmedetomidine or remifentanil better moderates the heart and blood pressure surges during electroconvulsive therapy in adults.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years to 60 Years
SexAll
Enrollment24 (estimated)
SponsorInonu University
Academic / other
Locations1 site (Malatya, Battalgazi)
StatusRecruiting
StartedSeptember 21, 2026
Main results expectedFebruary 1, 2027
Study endsApril 15, 2027
Registry record updatedSeptember 29, 2026
Trial IDNCT07824817 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18–60 with ASA I–II status scheduled for six ECT sessions for psychiatric conditions.

Probably not a fit

Patients with contraindications to dexmedetomidine or remifentanil, or those outside the 18–60 age range, may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional phase 4 trial compares two anesthetic adjuncts, dexmedetomidine and remifentanil, with saline as a control, in patients undergoing six ECT sessions. The goal is to see which option most effectively moderates acute hemodynamic responses while preserving seizure quality and enabling rapid recovery. Participants are adults aged 18–60 with ASA I–II undergoing ECT for various psychiatric conditions. Outcomes focus on hemodynamic stability, seizure duration/quality, and recovery profile, with safety monitoring for drug-related adverse events. The study builds on prior use of these agents to improve intraoperative stability and minimize sympathetic activation during ECT.

Why it matters

Potential benefit: If successful, patients could experience more stable blood pressure and heart rate during ECT with quicker recovery times.

How similar studies have gone: Prior studies have shown hemodynamic stabilization with both agents in various settings; this study tests their specific impact during ECT.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Upremedicated ASA I-II (American Society of Anesthesiologists's physical status) patients,
* Patients scheduled for six ECT sessions for a variety of psychiatric conditions

Exclusion Criteria:

* refusal to participate,
* age below 18 or above 60 years
* pregnancy
* asthma
* current use of β-adrenergic blockers
* myocardial infarction within the previous six months
* atrial fibrillation or atrial flutter,
* heart block
* a known personal or family history of hypersensitivity to any of the study drugs

Where it's running

  • Inonu Universitesi Turgut Ozal Tıp Merkezi
    Malatya, Battalgazi, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.